MyFinsight
Home
Blog
About
Contact
Download
Download image
Cash
$12,835,454
Reimbursement right
$2,297,806
Prepaid expenses and
other current assets
$1,615,096
Due from related
party
$638
Intangible assets
$114,300,000
Goodwill
$25,744,143
Total current assets
$16,748,994
Property and equipment,
net of depreciation
$346,745
Deferred offering costs
$25,000
Total assets
$157,164,882
Total liabilities,
series a non-voting...
$157,164,882
Series a non-voting
convertible preferred stock...
$143,269,761
Total liabilities
$12,643,694
Total stockholders'
equity
$1,251,427
Accumulated deficit
-$115,648,063
Long-term liabilities
$7,265,124
Total current
liabilities
$5,378,570
Additional paid-in capital
$116,899,277
Non-voting convertible
preferred stock
$121
Common stock - 0.0001
par value per share...
$92
Contingent consideration
$6,248,000
Warrant liability
$559,747
Deferred tax liability
$457,377
Accounts payable and
accrued expenses
$5,293,308
Back
Back
Balance Sheet
Transcode Therapeutics, Inc. (RNAZ)
Transcode Therapeutics, Inc. (RNAZ)
source: myfinsight.com